In the News
Press Releases
Alzheon Announces Initiation of Clinical Studies with ALZ‐801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease
Phase 1b Multiple Dose‐Ranging Study and Tablet Bioequivalence Study Will Provide Clinical Dose and Tablet Formulation Data to Support ALZ‐801 Phase 3 Program FRAMINGHAM, Mass., November [...]
Alzheon Appoints Susan Abushakra, M.D., as Chief Medical Officer
FRAMINGHAM, Mass., September 9, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological [...]
Alzheon Establishes New Corporate Headquarters
Expanded Facility Supports Business and Clinical Operations to Drive Future Pivotal Study of ALZ-801 in Patients with Alzheimer’s Disease FRAMINGHAM, Mass., April 8, 2015 -- Alzheon, [...]
Alzheon Announces $10 Million Series A Financing
Funding to Advance ALZ-801 Toward a Pivotal Clinical Study in Alzheimer’s Disease FRAMINGHAM, Mass., April 8, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on [...]
Alzheon Announces Phase 1 Results of ALZ-801, a First-in-Class Inhibitor of Amyloid Formation and Neurotoxicity for Alzheimer’s Disease
Phase 1 data demonstrated superior properties for ALZ-801 as an optimized prodrug of tramiprosate Clinical program for ALZ-801 supported by expanded post-hoc Phase 3 analyses with tramiprosate [...]
Alzheon Announces Patent Allowance in Europe for ALZ-801 in Development for Alzheimer’s Disease
LEXINGTON, Mass., January 5, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the European Patent Office [...]